BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB; European Paediatric Research Group for HUS. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006;70:423-31. [PMID: 16775594 DOI: 10.1038/sj.ki.5001581] [Cited by in Crossref: 199] [Cited by in F6Publishing: 144] [Article Influence: 12.4] [Reference Citation Analysis]
Number Citing Articles
1 Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology 2012;217:235-43. [PMID: 21852019 DOI: 10.1016/j.imbio.2011.07.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
2 Bajracharya P, Jain A, Baracco R, Mattoo TK, Kapur G. Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatr Nephrol 2016;31:1615-24. [PMID: 27139899 DOI: 10.1007/s00467-016-3369-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
3 Duran MN, Beyazit F, Erbaş M, Özkavak O, Acar C, Bakirdogen S. Successful treatment with eculizumab in a patient with pregnancy-associated atypical hemolytic uremic syndrome. Obstet Med. [DOI: 10.1177/1753495x211019902] [Reference Citation Analysis]
4 Noris M, Remuzzi G. Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology 2010;30:395-408. [DOI: 10.1016/j.semnephrol.2010.06.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
5 Johnson SA, Wong EK, Taylor CM. Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol 2014;29:1883-94. [PMID: 23852337 DOI: 10.1007/s00467-013-2559-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars 2015;50:73-82. [PMID: 26265890 DOI: 10.5152/tpa.2015.2297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
7 Gosain R, Gill A, Fuqua J, Volz LH, Kessans Knable MR, Bycroft R, Seger S, Gosain R, Rios JA, Chao JH. Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep 2017;5:1926-30. [PMID: 29225827 DOI: 10.1002/ccr3.1214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
8 Cheng M, Lin J, Yen T, Wang H, Chen M, Huang H, Chih H, Wang W. Thrombotic microangiopathy complicating newly diagnosed Sjögren’s syndrome in a dialysis patient. Renal Failure 2014;36:1162-5. [DOI: 10.3109/0886022x.2014.917764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billström R, Björk P, Holmberg L, Karpman D. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 2007;166:249-57. [PMID: 17187257 DOI: 10.1007/s00431-006-0354-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
10 Shawky S, Safouh H, Gamal M, Abbas MM, Aboul-Enein A, Sawai T, Fahmy Y, Selim H. Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome. Int J Nephrol 2021;2021:6904858. [PMID: 34840826 DOI: 10.1155/2021/6904858] [Reference Citation Analysis]
11 Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83-177. [PMID: 20568098 DOI: 10.1002/jca.20240] [Cited by in Crossref: 366] [Cited by in F6Publishing: 303] [Article Influence: 30.5] [Reference Citation Analysis]
12 Watanabe T. Renal complications of seasonal and pandemic influenza A virus infections. Eur J Pediatr 2013;172:15-22. [PMID: 23064728 DOI: 10.1007/s00431-012-1854-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
13 Karpman D, Tati R. Complement activation in thrombotic microangiopathy. Hamostaseologie 2013;33:96-104. [PMID: 23411690 DOI: 10.5482/HAMO-12-12-0025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1312-6. [PMID: 19556379 DOI: 10.2215/CJN.01090209] [Cited by in Crossref: 113] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
15 Mark Taylor C. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol 2008;23:1425-31. [PMID: 18493800 DOI: 10.1007/s00467-008-0820-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
16 Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:1920-1924. [PMID: 19820137 DOI: 10.2215/cjn.02730409] [Cited by in Crossref: 129] [Cited by in F6Publishing: 66] [Article Influence: 9.9] [Reference Citation Analysis]
17 Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program. 2011;2011:15-20. [PMID: 22160007 DOI: 10.1182/asheducation-2011.1.15] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
18 Zhang C, Meng Y, Liu Q, Xuan M, Zhang L, Deng B, Zhang K, Liu Z, Lei T. Injury to the endothelial surface layer induces glomerular hyperfiltration rats with early-stage diabetes. J Diabetes Res 2014;2014:953740. [PMID: 24812636 DOI: 10.1155/2014/953740] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
19 Frazer-abel A, Sepiashvili L, Mbughuni M, Willrich M. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Elsevier; 2016. pp. 1-75. [DOI: 10.1016/bs.acc.2016.06.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
20 Mörtzell M, Berlin G, Nilsson T, Axelsson C, Efvergren M, Audzijoni J, Griskevicius A, Ptak J, Blaha M, Tomsova H, Liumbruno G, Centoni P, Newman E, Eloot S, Dhondt A, Tomaz J, Witt V, Rock G, Stegmayr B. Thrombotic microangiopathy. Transfusion and Apheresis Science 2011;45:119-23. [DOI: 10.1016/j.transci.2011.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 Nangaku M, Nishi H, Fujita T. Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol 2007;11:107-14. [DOI: 10.1007/s10157-007-0466-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
22 Ge S, Hertel B, Emden SH, Beneke J, Menne J, Haller H, von Vietinghoff S. Microparticle generation and leucocyte death in Shiga toxin-mediated HUS. Nephrol Dial Transplant. 2012;27:2768-2775. [PMID: 22234918 DOI: 10.1093/ndt/gfr748] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
23 Asano S, Taneda M, Katoh K, Suzuki K. Life-threatening hemorrhagic shock after laparoscopic surgery: a case of postoperative thrombotic thrombocytopenic purpura. J Anesth 2012;26:766-9. [PMID: 22526435 DOI: 10.1007/s00540-012-1392-8] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
24 Printza N, Sapountzi E, Dotis J, Papachristou F. Hemolytic uremic syndrome related to cryptosporidium infection in an immunocompetent child: Cryptosporidium-induced HUS. Pediatr Int 2013;55:788-90. [DOI: 10.1111/ped.12127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
25 Alpers CE. The Kidney. Robbins and Cotran Pathologic Basis of Disease. Elsevier; 2010. pp. 905-69. [DOI: 10.1016/b978-1-4377-0792-2.50025-0] [Cited by in Crossref: 13] [Article Influence: 1.1] [Reference Citation Analysis]
26 Herget-Rosenthal S. Thrombotic microangiopathies--an issue for intensivists? Acta Clin Belg 2007;62 Suppl 2:385-8. [PMID: 18284005 DOI: 10.1179/acb.2007.086] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
27 Kang J, Lee D, Park Y. Atypical Hemolytic Uremic Syndrome after Traumatic Rectal Injury: A Case Report. J Trauma Inj 2021;34:299-304. [DOI: 10.20408/jti.2020.0068] [Reference Citation Analysis]
28 Ballermann BJ. Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol. 2007;106:p19-p25. [PMID: 17570944 DOI: 10.1159/000101796] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
29 Nguyen QV, Hochstrasser L, Chuard C, Hächler H, Regamey C, Descombes E. Adult hemolytic-uremic syndrome associated with urosepsis due to Shigatoxin-producing Escherichia coli O138:H-. Ren Fail 2007;29:747-50. [PMID: 17763172 DOI: 10.1080/08860220701460418] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
30 Lee MD, Tzen CY, Lin CC, Huang FY, Liu HC, Tsai JD. Hemolytic uremic syndrome caused by enteroviral infection. Pediatr Neonatol 2013;54:207-10. [PMID: 23597514 DOI: 10.1016/j.pedneo.2012.10.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Jokiranta TS, Zipfel PF, Fremeaux-bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical hemolytic uremic syndrome? Molecular Immunology 2007;44:3889-900. [DOI: 10.1016/j.molimm.2007.06.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
32 Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 2018;103:285-91. [PMID: 28899876 DOI: 10.1136/archdischild-2016-311377] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
33 Menon MC, Chuang PY, He CJ. The glomerular filtration barrier: components and crosstalk. Int J Nephrol. 2012;2012:749010. [PMID: 22934182 DOI: 10.1155/2012/749010] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
34 Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL. Thrombotic thrombocytopenic purpura in childhood: Thrombotic Thrombocytopenic Purpura in Childhood. Pediatr Blood Cancer 2009;53:537-42. [DOI: 10.1002/pbc.22094] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
35 Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2009;20:940-949. [PMID: 19092117 DOI: 10.1681/asn.2008080906] [Cited by in Crossref: 127] [Cited by in F6Publishing: 51] [Article Influence: 9.1] [Reference Citation Analysis]
36 Szilágyi A, Kiss N, Bereczki C, Tálosi G, Rácz K, Túri S, Györke Z, Simon E, Horváth E, Kelen K, Reusz GS, Szabó AJ, Tulassay T, Prohászka Z. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013;28:2237-45. [PMID: 23787556 DOI: 10.1093/ndt/gft198] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
37 Stritt A, Tschumi S, Kottanattu L, Bucher BS, Steinmann M, von Steiger N, Stephan R, Hachler H, Simonetti GD. Neonatal Hemolytic Uremic Syndrome After Mother-to-Child Transmission of a Low-Pathogenic stx2b Harboring Shiga Toxin-Producing Escherichia coli. Clinical Infectious Diseases 2012;56:114-6. [DOI: 10.1093/cid/cis851] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
38 Ostini A, Simonetti GD, Pellanda G, Bianchetti MG, Ferrarini A, Milani GP. Familial Henoch-Schönlein Syndrome. J Clin Rheumatol 2016;22:80-1. [PMID: 26906300 DOI: 10.1097/RHU.0000000000000360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
39 Ballermann BJ, Stan RV. Resolved: capillary endothelium is a major contributor to the glomerular filtration barrier. J Am Soc Nephrol 2007;18:2432-8. [PMID: 17724232 DOI: 10.1681/ASN.2007060687] [Cited by in Crossref: 58] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
40 Hirahashi J, Hishikawa K, Kaname S, Tsuboi N, Wang Y, Simon DI, Stavrakis G, Shimosawa T, Xiao L, Nagahama Y, Suzuki K, Fujita T, Mayadas TN. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation 2009;120:1255-65. [PMID: 19752320 DOI: 10.1161/CIRCULATIONAHA.109.873695] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
41 Erpenbeck L, Demers M, Zsengellér ZK, Gallant M, Cifuni SM, Stillman IE, Karumanchi SA, Wagner DD. ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy. J Am Soc Nephrol 2016;27:120-31. [PMID: 26038528 DOI: 10.1681/ASN.2014121165] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol 2013; 2(3): 56-76 [PMID: 24255888 DOI: 10.5527/wjn.v2.i3.56] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
43 Bowen EE, Hangartner R, Macdougall I. Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome. J Gen Intern Med 2016;31:353-6. [PMID: 26001543 DOI: 10.1007/s11606-015-3403-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
44 Johnson S, Taylor CM. Hemolytic Uremic Syndrome. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1155-80. [DOI: 10.1007/978-3-540-76341-3_48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Nester CM. Multifaceted hemolytic uremic syndrome in pediatrics. Blood Purif 2013;35:86-92. [PMID: 23343552 DOI: 10.1159/000346486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Hertig A, Ridel C, Rondeau E. [Hemolytic uremic syndrome in adults]. Nephrol Ther 2010;6:258-71. [PMID: 20399168 DOI: 10.1016/j.nephro.2010.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
47 Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med. 2012;41:e115-e135. [PMID: 22284541 DOI: 10.1016/j.lpm.2011.11.013] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
48 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
49 Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72. [PMID: 18594873 DOI: 10.1007/s00467-008-0872-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
50 Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB; European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009;24:687-96. [PMID: 18800230 DOI: 10.1007/s00467-008-0964-1] [Cited by in Crossref: 225] [Cited by in F6Publishing: 173] [Article Influence: 16.1] [Reference Citation Analysis]
51 Ferraris JR, Ferraris V, Acquier AB, Sorroche PB, Saez MS, Ginaca A, Mendez CF. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol 2015;181:118-25. [PMID: 25677399 DOI: 10.1111/cei.12601] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
52 Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3:CD012862. [PMID: 33783815 DOI: 10.1002/14651858.CD012862.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens: Meta-Analysis of Atypical HUS Case Reports. Therapeutic Apheresis and Dialysis 2018;22:178-88. [DOI: 10.1111/1744-9987.12641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
54 Çakar N, Ozcakar Z, Ozaltin F, Koyun M, Celikel acar B, Bahat E, Gulhan B, Korkmaz E, Yurt A, Yılmaz S, Soylemezoglu O, Yalcinkaya F. Atypical Hemolytic Uremic Syndrome in Children Aged <2 Years. Nephron 2018;139:211-8. [DOI: 10.1159/000487609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
55 Schifferli A, von Vigier RO, Fontana M, Spartà G, Schmid H, Bianchetti MG, Rudin C; Swiss Pediatric Surveillance Unit. Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997-2003. Eur J Pediatr 2010;169:591-8. [PMID: 19830454 DOI: 10.1007/s00431-009-1079-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
56 Buder K, Latal B, Nef S, Neuhaus TJ, Laube GF, Spartà G. Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome. Pediatr Nephrol 2015;30:503-13. [PMID: 25234636 DOI: 10.1007/s00467-014-2950-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
57 Yasuda K, Sasaki K, Yamato M, Rakugi H, Isaka Y, Hayashi T, Piras R, Bresin E. Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection. CEN Case Rep 2013;2:34-7. [PMID: 28509219 DOI: 10.1007/s13730-012-0034-1] [Reference Citation Analysis]
58 Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 2012;27:2327-31. [PMID: 22903728 DOI: 10.1007/s00467-012-2283-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
59 Gilbert RD, Stanley LK, Fowler DJ, Angus EM, Hardy SA, Goodship TH. Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab. Clin Kidney J 2013;6:421-5. [PMID: 24422172 DOI: 10.1093/ckj/sft065] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
60 Nadasdy T. Thrombotic microangiopathy in renal allografts: the diagnostic challenge. Curr Opin Organ Transplant. 2014;19:283-292. [PMID: 24811438 DOI: 10.1097/mot.0000000000000074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
61 Jenssen GR, Hovland E, Bjerre A, Bangstad HJ, Nygard K, Vold L. Incidence and etiology of hemolytic-uremic syndrome in children in Norway, 1999-2008--a retrospective study of hospital records to assess the sensitivity of surveillance. BMC Infect Dis 2014;14:265. [PMID: 24884396 DOI: 10.1186/1471-2334-14-265] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
62 Boels MG, Lee DH, van den Berg BM, Dane MJ, van der Vlag J, Rabelink TJ. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome. Eur J Intern Med 2013;24:503-9. [PMID: 23357408 DOI: 10.1016/j.ejim.2012.12.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
63 Geelen JM, van der Velden TJ, van den Heuvel LP, Monnens LA. Interactions of Shiga-like toxin with human peripheral blood monocytes. Pediatr Nephrol 2007;22:1181-7. [PMID: 17574480 DOI: 10.1007/s00467-007-0512-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
64 Reusz G, Szabó A, Réti M, Györke Z, Szilágyi Á, Farkas P, Prohászka Z. Diagnosis and Classification of Hemolytic Uremic Syndrome: The Hungarian Experience. Transplantation Proceedings 2011;43:1247-9. [DOI: 10.1016/j.transproceed.2011.03.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
65 Rhee H, Song SH, Lee YJ, Choi HJ, Ahn JH, Seong EY, Lee SB, Kwak IS. Pandemic H1N1 influenza A viral infection complicated by atypical hemolytic uremic syndrome and diffuse alveolar hemorrhage. Clin Exp Nephrol 2011;15:948-52. [PMID: 21826588 DOI: 10.1007/s10157-011-0516-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
66 Dedhia P, Govil A, Mogilishetty G, Alloway RR, Woodle ES, Abu Jawdeh BG. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. Transplant Proc. 2017;49:188-192. [PMID: 28104134 DOI: 10.1016/j.transproceed.2016.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
67 Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 2017;32:297-309. [PMID: 27718086 DOI: 10.1007/s00467-016-3496-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
68 Moretti M, Lava SA, Zgraggen L, Simonetti GD, Kottanattu L, Bianchetti MG, Milani GP. Acute kidney injury in symptomatic primary Epstein-Barr virus infectious mononucleosis: Systematic review. Journal of Clinical Virology 2017;91:12-7. [DOI: 10.1016/j.jcv.2017.03.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
69 Verbiest A, Pirenne J, Dierickx D. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Reviews 2014;28:269-79. [DOI: 10.1016/j.blre.2014.09.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
70 Kitai Y, Matsubara T, Yanagita M. Onco-nephrology: current concepts and future perspectives. Japanese Journal of Clinical Oncology 2015;45:617-28. [DOI: 10.1093/jjco/hyv035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
71 Koppula S, Yost SE, Sussman A, Bracamonte ER, Kaplan B. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. Clin Transplant. 2013;27:591-597. [PMID: 23923969 DOI: 10.1111/ctr.12170] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
72 Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E, Pilato FP, Valoti E, Pasquali S, Buzio C. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrology Dialysis Transplantation 2013;28:2246-59. [DOI: 10.1093/ndt/gft220] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
73 Pelras S, Delmas Y, Lamireau D, Villega F, Nolent P, Ryman A, Llanas B, Brissaud O, Harambat J. Severe transient ADAMTS13 deficiency in pneumococcal-associated hemolytic uremic syndrome. Pediatr Nephrol 2011;26:631-5. [PMID: 21161282 DOI: 10.1007/s00467-010-1721-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
74 Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, Bruijn JA, Bajema IM, Cohen D. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. J Am Soc Nephrol. 2015;26:2239-2247. [PMID: 25573909 DOI: 10.1681/asn.2014050429] [Cited by in Crossref: 62] [Cited by in F6Publishing: 25] [Article Influence: 8.9] [Reference Citation Analysis]
75 Lavin PJ, Gbadegesin R, Damodaran TV, Winn MP. Therapeutic targets in focal and segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 2008;17:386-92. [PMID: 18660675 DOI: 10.1097/MNH.0b013e32830464f4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
76 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
77 Jenssen GR, Vold L, Hovland E, Bangstad HJ, Nygård K, Bjerre A. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008. BMC Infect Dis 2016;16:285. [PMID: 27297224 DOI: 10.1186/s12879-016-1627-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
78 Morel N, Berthoux E, Colombe B, Bosseray A, Massot C. Micro-angiopathie thrombotique avec anticorps anti-ADAMTS 13 révélant une fièvre Q aiguë. La Revue de Médecine Interne 2012;33:640-2. [DOI: 10.1016/j.revmed.2012.08.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
79 Mittal N, Hartemayer R, Jandeska S, Giordano L. Steroid Responsive Atypical Hemolytic Uremic Syndrome Triggered by Influenza B Infection. J Pediatr Hematol Oncol 2019;41:e63-7. [PMID: 29702545 DOI: 10.1097/MPH.0000000000001180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
80 Karpman D, Ståhl AL, Arvidsson I, Johansson K, Loos S, Tati R, Békássy Z, Kristoffersson AC, Mossberg M, Kahn R. Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. Adv Exp Med Biol 2015;865:19-42. [PMID: 26306441 DOI: 10.1007/978-3-319-18603-0_2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
81 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
82 Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2015;165:306-20. [PMID: 25468487 DOI: 10.1016/j.trsl.2014.10.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
83 Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 2012;27:2323-6. [PMID: 22890512 DOI: 10.1007/s00467-012-2276-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
84 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
85 Huang SH, Xenocostas A, Moist LM, Crowther M, Moore JC, Clark WF. Ustekinumab associated thrombotic thrombocytopenic purpura. Transfus Apher Sci 2012;47:185-8. [PMID: 22858359 DOI: 10.1016/j.transci.2012.06.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
86 Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. [PMID: 20595690 DOI: 10.2215/cjn.02210310] [Cited by in Crossref: 584] [Cited by in F6Publishing: 274] [Article Influence: 48.7] [Reference Citation Analysis]
87 Godron A, Pereyre S, Monet C, Llanas B, Harambat J. Hemolytic uremic syndrome complicating Mycoplasma pneumoniae infection. Pediatr Nephrol 2013;28:2057-60. [PMID: 23800801 DOI: 10.1007/s00467-013-2541-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
88 Bitzan M, Lapeyraque A. Postinfectious Hemolytic Uremic Syndrome. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Berlin: Springer Berlin Heidelberg; 2016. pp. 653-731. [DOI: 10.1007/978-3-662-52972-0_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
89 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
90 Prohászka Z, Varga L, Füst G. The use of ‘real-time’ complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies. Br J Haematol 2012;158:424-5. [DOI: 10.1111/j.1365-2141.2012.09168.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
91 Sugimoto T, Hajiro T, Fujimoto T, Kojyo N, Horie M, Kashiwagi A. Thrombotic microangiopathy in an adult patient with clinically amyopathic dermatomyositis complicated with interstitial lung disease. Lupus 2007;16:1004-5. [PMID: 18042598 DOI: 10.1177/0961203307082382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
92 Kaplan BS, Ruebner RL, Copelovitch L. Eculizumab treatment of atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2012. [DOI: 10.1080/21678707.2013.750579] [Reference Citation Analysis]
93 Adams C, Vose A, Edmond MB, Lyckholm L. Shigella sonnei and hemolytic uremic syndrome: A case report and literature review. IDCases 2017;8:6-8. [PMID: 28239557 DOI: 10.1016/j.idcr.2017.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Caeiro Alves F, Aguiar R, Pessegueiro P, Pires C. Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. BMJ Case Rep 2018;2018:bcr-2017-222582. [PMID: 29550758 DOI: 10.1136/bcr-2017-222582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
95 Kościelska-Kasprzak K, Bartoszek D, Myszka M, Zabińska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz) 2014;62:47-57. [PMID: 24030732 DOI: 10.1007/s00005-013-0254-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
96 Loirat C, Fremeaux-bacchi V. Recurrence of haemolytic uraemic syndrome after renal transplantation. Current Opinion in Organ Transplantation 2007;12:496-502. [DOI: 10.1097/mot.0b013e3282ef3d64] [Reference Citation Analysis]
97 Leban N, Aloui S, Touati D, Lakhdhar R, Skhiri H, Lefranc G, Achour A, Elmay M, Lopez-Trascasa M, Sanchez-Corral P, Chibani J, Haj Khelil A. Atypical hemolytic uremic syndrome in the Tunisian population. Int Urol Nephrol 2011;43:559-64. [PMID: 20499172 DOI: 10.1007/s11255-010-9754-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
98 Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013;3:e003573. [PMID: 24189082 DOI: 10.1136/bmjopen-2013-003573] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
99 Sexton DJ, Reule S, Solid CA, Chen SC, Collins AJ, Foley RN. End-stage renal disease from hemolytic uremic syndrome in the United States, 1995-2010. Hemodial Int 2015;19:521-30. [PMID: 25689876 DOI: 10.1111/hdi.12281] [Reference Citation Analysis]
100 Fridén V, Oveland E, Tenstad O, Ebefors K, Nyström J, Nilsson UA, Haraldsson B. The glomerular endothelial cell coat is essential for glomerular filtration. Kidney Int. 2011;79:1322-1330. [PMID: 21412215 DOI: 10.1038/ki.2011.58] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 7.5] [Reference Citation Analysis]
101 Tang W, Mohandas J, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, Clayton PA, Wiggins KJ, Bannister KM, Campbell SB, Johnson DW. End-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrol 2012;13:164. [PMID: 23206870 DOI: 10.1186/1471-2369-13-164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
102 Lee JW, Won NH, Cho E, Kim MG, Jo SK, Cho WY, Kim HK. Postoperative hemolytic uremic syndrome with renal cortical necrosis following laparoscopic hemicolectomy. Ren Fail 2013;35:725-8. [PMID: 23560430 DOI: 10.3109/0886022X.2013.780978] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
103 Abarrategui-Garrido C, Melgosa M, Peña-Carrión A, de Jorge EG, de Córdoba SR, López-Trascasa M, Sánchez-Corral P. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 2008;52:171-80. [PMID: 18423815 DOI: 10.1053/j.ajkd.2008.01.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
104 Matsukuma E, Imamura A, Iwata Y, Takeuchi T, Yoshida Y, Fujimura Y, Fan X, Miyata T, Kuwahara T. Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation. Case Rep Nephrol 2014;2014:784943. [PMID: 25431709 DOI: 10.1155/2014/784943] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
105 Darwin A, Malpica L, Dhanoa J, Hashmi H. Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. BMJ Case Rep 2021;14:e239091. [PMID: 33637496 DOI: 10.1136/bcr-2020-239091] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Sinha A, Singh G, Bhat AS, Mohapatra S, Gulati A, Hari P, Samantaray JC, Dinda AK, Agarwal SK, Bagga A. Thrombotic microangiopathy and acute kidney injury following vivax malaria. Clin Exp Nephrol 2013;17:66-72. [DOI: 10.1007/s10157-012-0656-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
107 Coats MT, Murphy T, Paton JC, Gray B, Briles DE. Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A. Microb Pathog 2011;50:343-9. [PMID: 21377521 DOI: 10.1016/j.micpath.2011.02.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
108 Taylor CM, Machin S, Wigmore SJ, Goodship TH; working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010;148:37-47. [PMID: 19821824 DOI: 10.1111/j.1365-2141.2009.07916.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 113] [Article Influence: 11.5] [Reference Citation Analysis]
109 Huzmeli C, Candan F, Seker A, Yildiz E, Terzi H, Kayatas M. C3 mesangial proliferative glomerulonephritis initially presenting with atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2016;10:206. [PMID: 27460033 DOI: 10.1186/s13256-016-0992-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
110 Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M, Ernst F, Selleng K, Weissenborn K, Schmidt BM, Schiffer M, Felix SB, Lerch MM, Kielstein JT, Mayerle J. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011;378:1166-73. [PMID: 21890192 DOI: 10.1016/S0140-6736(11)61253-1] [Cited by in Crossref: 105] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
111 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
112 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
113 Vester U, Mache CJ. Pharmacological treatment of atypical hemolytic-uremic syndrome. Expert Opinion on Orphan Drugs 2014;2:123-35. [DOI: 10.1517/21678707.2014.872029] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
114 Menon MC, Chuang PY, He CJ. The glomerular filtration barrier: components and crosstalk. Int J Nephrol 2012;2012:749010. [PMID: 22934182 DOI: 10.1155/2012/749010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Kichloo A, Chugh SS, Gupta S, Pandav J, Chander P. Atypical Hemolytic Uremic Syndrome Presenting as Acute Heart Failure-A Rare Presentation: Diagnosis Supported by Skin Biopsy. J Investig Med High Impact Case Rep 2019;7:2324709619842905. [PMID: 31010328 DOI: 10.1177/2324709619842905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Haddadin M, Al-Sadawi M, Madanat S, Tam E, Taiwo E, Luhrs C, Mcfarlane SI. Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy. Am J Med Case Rep 2019;7:240-3. [PMID: 31457071 DOI: 10.12691/ajmcr-7-10-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
117 Nguyen Q, Descombes E. Etiology-based classification of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. What about hemolytic uremic syndrome associated with urinary tract infections? Kidney International 2007;71:466. [DOI: 10.1038/sj.ki.5002061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
118 Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol 2008;23:1761-7. [PMID: 17906963 DOI: 10.1007/s00467-007-0616-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
119 Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673-2685. [PMID: 22802583 DOI: 10.1093/ndt/gfs279] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
120 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
121 Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1967-78. [PMID: 24817340 DOI: 10.1007/s00467-014-2817-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
122 Golgert WA, Appel GB, Hariharan S. Recurrent glomerulonephritis after renal transplantation: an unsolved problem. Clin J Am Soc Nephrol. 2008;3:800-807. [PMID: 18272827 DOI: 10.2215/cjn.04050907] [Cited by in Crossref: 52] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
123 Torres EA, Chang Y, Desai S, Chang I, Zuckerman JE, Burwick R, Kalantar-Zadeh K, Hanna RM. Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report. Case Rep Nephrol Dial 2021;11:95-102. [PMID: 33977097 DOI: 10.1159/000512227] [Reference Citation Analysis]
124 Malina M, Roumenina LT, Seeman T, Le Quintrec M, Dragon-Durey MA, Schaefer F, Fremeaux-Bacchi V. Genetics of hemolytic uremic syndromes. Presse Med 2012;41:e105-14. [PMID: 22265161 DOI: 10.1016/j.lpm.2011.10.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
125 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
126 Wu X, Szarzanowicz A, Garba A, Schaefer B, Waz WR. Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review. Cureus 2021;13:e19476. [PMID: 34912617 DOI: 10.7759/cureus.19476] [Reference Citation Analysis]
127 Rosales A, Riedl M, Zimmerhackl LB. Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol 2010;6:504-6. [PMID: 20736981 DOI: 10.1038/nrneph.2010.98] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
128 Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J Med Case Rep 2014;8:307. [PMID: 25219386 DOI: 10.1186/1752-1947-8-307] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
129 Ruebner RL, Kaplan BS, Copelovitch L. A time for reappraisal of "atypical" hemolytic uremic syndrome: should all patients be treated the same? Eur J Pediatr 2012;171:1519-25. [PMID: 22673930 DOI: 10.1007/s00431-012-1763-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
130 Vanaja SK, Jandhyala DM, Mallick EM, Leong JM, Balasubramanian S. Enterohemorrhagic and other Shigatoxin-producing Escherichia coli. Escherichia coli. Elsevier; 2013. pp. 121-82. [DOI: 10.1016/b978-0-12-397048-0.00005-x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
131 Kobbe R, Schild R, Christner M, Oh J, Loos S, Kemper MJ. Case report - atypical hemolytic uremic syndrome triggered by influenza B. BMC Nephrol 2017;18:96. [PMID: 28320387 DOI: 10.1186/s12882-017-0512-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
132 Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Würzner R, Jungraithmayr T; German-Austrian HUS Study Group. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013;8:407-15. [PMID: 23243267 DOI: 10.2215/CJN.01260212] [Cited by in Crossref: 80] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
133 Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008;23:1749-60. [PMID: 18704506 DOI: 10.1007/s00467-008-0935-6] [Cited by in Crossref: 183] [Cited by in F6Publishing: 140] [Article Influence: 13.1] [Reference Citation Analysis]
134 Johnson S, Taylor CM. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965-71. [PMID: 18575887 DOI: 10.1007/s00431-008-0745-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
135 Schiller O, Ash S, Schonfeld T, Kadmon G, Nahum E, Yacobovich J, Tamary H, Davidovits M. Postoperative thrombotic thrombocytopenic purpura in an infant: case report and literature review. J Pediatr Surg 2011;46:764-6. [PMID: 21496552 DOI: 10.1016/j.jpedsurg.2011.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
136 Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014;85:1151-1160. [PMID: 24088957 DOI: 10.1038/ki.2013.373] [Cited by in Crossref: 117] [Cited by in F6Publishing: 91] [Article Influence: 13.0] [Reference Citation Analysis]
137 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
138 Kim AY, Cho KH, Kang SH, Park JW, Do JY, Kim MK. Hemolytic uremic syndrome caused by sea anemone sting: a case report. BMC Nephrol 2021;22:14. [PMID: 33413182 DOI: 10.1186/s12882-020-02218-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Agarwal HS, Latifi SQ. Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine. Pathogens 2021;10:727. [PMID: 34207609 DOI: 10.3390/pathogens10060727] [Reference Citation Analysis]
140 Prohászka Z. [Haemolytic uremic syndrome and thrombotic thrombocytopenic purpura: classification based on molecular etiology and review of recent developments in diagnostics]. Orv Hetil 2008;149:1251-61. [PMID: 18579464 DOI: 10.1556/OH.2008.28367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
141 Compostella A, Pasetto L, Ghiotto C, Stefani M, Monfardini S. Oxaliplatin-Induced Haemolytic Anaemia: A Case Report. Clinical medicine Oncology 2007;1:117955490700100. [DOI: 10.1177/117955490700100003] [Reference Citation Analysis]
142 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
143 Allen U, Licht C. Pandemic H1N1 influenza A infection and (atypical) HUS--more than just another trigger? Pediatr Nephrol 2011;26:3-5. [PMID: 21057815 DOI: 10.1007/s00467-010-1690-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
144 Abu Jawdeh BG, Govil A. Acute Kidney Injury in Transplant Setting: Differential Diagnosis and Impact on Health and Health Care. Adv Chronic Kidney Dis 2017;24:228-32. [PMID: 28778362 DOI: 10.1053/j.ackd.2017.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
145 Manea M, Karpman D. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. Pediatr Nephrol 2009;24:447-58. [DOI: 10.1007/s00467-008-0986-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
146 Cao M, Ferreiro T, Leite BN, Pita F, Bolaños L, Valdés F, Alonso A, Vázquez E, Mosquera J, Trigás M, Rodríguez S. Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. CEN Case Rep 2017;6:91-7. [PMID: 28509134 DOI: 10.1007/s13730-017-0251-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
147 Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, Gomez Danies H, Kellum JA. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Crit Care Clin 2020;36:333-56. [PMID: 32172817 DOI: 10.1016/j.ccc.2019.11.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
148 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
149 Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 2011;17:5858-66. [PMID: 21813634 DOI: 10.1158/1078-0432.CCR-11-0804] [Cited by in Crossref: 62] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
150 Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011;6:1488-1494. [PMID: 21617085 DOI: 10.2215/cjn.10181110] [Cited by in Crossref: 91] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
151 Arvidsson I, Ståhl AL, Hedström MM, Kristoffersson AC, Rylander C, Westman JS, Storry JR, Olsson ML, Karpman D. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 2015;194:2309-18. [PMID: 25637016 DOI: 10.4049/jimmunol.1402470] [Cited by in F6Publishing: 47] [Reference Citation Analysis]
152 Gibson KL, Gipson DS, Massengill SF. Renal manifestations of systemic illness in children. Semin Nephrol 2009;29:360-9. [PMID: 19615557 DOI: 10.1016/j.semnephrol.2009.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
153 Dierickx D, De Rycke A, Vanderschueren S, Delannoy A. New treatment options for immune-mediated hematological disorders. European Journal of Internal Medicine 2008;19:579-86. [DOI: 10.1016/j.ejim.2007.08.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
154 Nikolajeva O, Worth A, Hague R, Martinez-Alier N, Smart J, Adams S, Davies EG, Gaspar HB. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome. J Clin Immunol 2015;35:366-72. [PMID: 25875700 DOI: 10.1007/s10875-015-0158-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
155 Webster K, Schnitzler E. Hemolytic uremic syndrome. Handb Clin Neurol 2014;120:1113-23. [PMID: 24365375 DOI: 10.1016/B978-0-7020-4087-0.00075-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
156 Ståhl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008;111:5307-15. [PMID: 18268093 DOI: 10.1182/blood-2007-08-106153] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 7.2] [Reference Citation Analysis]
157 Tati R, Kristoffersson AC, Ståhl AL, Rebetz J, Wang L, Licht C, Motto D, Karpman D. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013;191:2184-93. [PMID: 23878316 DOI: 10.4049/jimmunol.1301221] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
158 Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2017;32:466-74. [PMID: 28339660 DOI: 10.1093/ndt/gfw453] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 13.4] [Reference Citation Analysis]
159 Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 2013;28:155-8. [PMID: 22956028 DOI: 10.1007/s00467-012-2296-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
160 Franchini M. Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clinical Chemistry and Laboratory Medicine (CCLM) 2015;53. [DOI: 10.1515/cclm-2015-0024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
161 Carter CE, Benador NM. Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol 2014;29:35-50. [PMID: 23812351 DOI: 10.1007/s00467-013-2479-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]